Premium
Rapid modifications of peripheral T‐cell subsets that express CD127 in macaques treated with recombinant IL‐7
Author(s) -
DereuddreBosquet Nathalie,
Vaslin Bruno,
Delache Benoit,
Brochard Patricia,
Clayette Pascal,
Aubenque Céline,
Morre Michel,
Assouline Brigitte,
Le Grand Roger
Publication year - 2007
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/j.1600-0684.2007.00240.x
Subject(s) - interleukin 7 receptor , cd8 , cd3 , biology , t cell , immunology , lymphocyte , peripheral blood lymphocyte , interleukin 2 , peripheral , flow cytometry , recombinant dna , medicine , endocrinology , immune system , il 2 receptor , biochemistry , gene
Background Interleukin‐7 (IL‐7) is a key regulator of thymopoiesis and T‐cell homeostasis, which increases blood T‐cell number by enhancing thymic output of naive cells and peripheral proliferation. Methods We explored the effects of unglycosylated recombinant simian IL‐7 (rsIL‐7) administration on peripheral T‐cell subpopulations in healthy macaques. Results RsIL‐7 was well tolerated. Mean half‐life ranged between 9.3 and 13.9 hours. Blood CD3 + CD4 + and CD3 + CD8 + lymphocyte counts decreased rapidly after each rsIL‐7 administration, the duration of these effects being dependent on the frequency of administration. At treatment completion, the increased of CD3 + lymphocytes was marked at 100 μg/kg every 2 days. CD3 + lymphocytes that harbour the alpha chain of IL‐7 receptor (CD127) and CD3 + CD8 + lymphocytes that expressed the proliferation marker Ki‐67 exhibited a similar initial profile. The expression of the anti‐apoptotic marker Bcl‐2 increased in CD3 + lymphocytes during the treatment and post‐treatment period in a dose/frequency dependent manner. Conclusion RsIL‐7 was well tolerated in macaques and induces rapid modifications of T‐cells that express CD127.